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Abstract 
BACKGROUND: Parkinson’s disease (PD) has been associated with peripheral 
neuropathy (PN). PN has been demonstrated in some rare genetic forms of PD (e.g. 
PARK2 mutations) but has also been linked to levodopa exposure.  
OBJECTIVE: The aim of this systematic review is to clarify any evidence of peripheral 
nervous system involvement in idiopathic PD.  
METHODS: A systematic computer-based literature search was conducted on 
PubMed database.  
FINDINGS: The pooled estimate of the prevalence of large fiber PN in PD was 16.3% 
(based on 1,376 patients). The pooled estimate of the prevalence of biopsy-proven 
small fiber neuropathy was 56.9% (based on 72 patients).  
Large fiber PN in PD is in the majority of cases distal, symmetrical, axonal and 
predominantly sensory. There are, however, few reports of chronic idiopathic 
demyelinating polyneuropathy and very occasional cases of acute neuropathies. 
Although nerve conduction studies have been performed in the majority of the 
studies, they included only a limited number of nerves, mainly in the lower limbs . 
There is little evidence to support a direct link between levodopa treatment and the 
development of PN in idiopathic PD. In the majority of the cases PN has been linked 
to abnormalities in vitamin B12, methylmalonic acid or fasting homocysteine levels. 
Additional aetiological risk factors for PN may be responsible for any apparent link 
between PD and PN. 
CONCLUSIONS: Large-scale prospective studies with long-term follow-up with 
detailed baseline assessments are needed in order to understand the natural history 
of PN in PD, both on clinical and neurophysiological parameters. 
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1. Introduction 
 
The term peripheral neuropathy (PN) refers to any disorder of the peripheral 
nervous system including single and multiple mononeuropathies (i.e. mononeuritis 
multiplex), symmetrical involvement of many nerves (polyneuropathy) or isolated 
involvement of sensory ganglia (ganglionopathies) [1]. Further classification depends 
on a mixture of phenomenological, neurophysiological, pathological and aetiological 
parameters [2]. There is sparse robust epidemiological data on polyneuropathies of 
any cause in the general population, the current estimates being between 2.4% and 
8.0% [3 – 5]. Population-based studies have shown that prevalence of PN increases 
with age [5], being a common cause of chronic pain in the elderly [6].  
 
An association between PN and Parkinson’s disease (PD) has been described in some 
rare genetic forms of PD, such as in patients with PARK2 mutations [7] and has also 
been linked to levodopa exposure [8].  
 
The aim of this work was systematically to review available studies on PN in 
idiopathic Parkinson’s disease (IPD) in an attempt to clarify causal mechanisms of 
peripheral nervous system involvement in IPD.  
 
2. Methods 
 
Literature Search Strategy 
 
A systematic computer-based literature search was conducted on April 9th, 2017 
using the PubMed database. For the search we used two Medical Subject Headings 
(MeSH) terms in title or abstract. Term A was “Parkinson” or “Parkinson’s” and Term 
B was “neuropathy” OR “polyneuropathy”. Limitations included human species, 
English language and full text available. We also perused the reference lists of the 
papers in order to find papers not identified through the search strategy. 
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Inclusion and exclusion criteria 
 
To be included in the review, the articles had to meet the following criteria:  
(1) to involve single cases or cases series with the combination of PN and IPD,  
(2) to study human adult subjects 
 
Exclusion criteria included: 
(1) book chapters, reviews, letters to the editor and editorials not providing new 
data. 
(2) Papers referring only to autonomic neuropathy. 
 
3. Results 
 
Search results 
 
This search strategy resulted in the identification of 278 articles. After the eligibility 
assessment, 243 articles were excluded and 35 met the inclusion criteria. Scanning 
the reference lists 3 more papers were identified. In total, 38 papers were used for 
this review. Table 1 summarizes the characteristics of these papers (full details for 
each study are available as an online Supplement). Figure 1 illustrates the study 
selection process.  
 
 
Epidemiology of large fiber neuropathy 
 
Large fiber neuropathy occurs when the Aα and Aβ myelinated fibers are affected 
and is diagnosed via nerve conduction studies. The first report of patients with PD 
who developed PN was in 1991 (Bulling et al., [9]). The prevalence of large fiber 
neuropathy in IPD ranges from 6% to 58% [10 – 12]. The pooled estimate of the 
prevalence of large fiber neuropathy reported in 17 studies with a total of 1,376 
patients was 16.3%. This is higher than the prevalence of PN in the general 
population [3, 4].  
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As shown in Table 1, the male:female ratio of patients with PD who developed PN is 
identical to the gender ratio of the patients with PD who did not develop PN. The 
mean age of patients who developed PN is higher compared to the mean of the 
studied populations (69.4 versus 66.0 years respectively).  
 
Epidemiology of small fiber neuropathy 
 
In small fiber neuropathy (SFN), the unmyelinated C and the thinly myelinated Ad 
fibers are affected. The clinical features (i.e. pinprick and thermal sensory loss, 
allodynia, hyperalgesia etc.), results of associated special investigations (i.e. 
quantitative sensory testing and altered intra-epidermal nerve fibre density) and 
normal nerve conduction studies are used to diagnose SFN [13]. Skin biopsy, as it is 
objective, appears to have greater diagnostic precision than the clinical examination 
and quantitative sensory testing in the diagnosis of small fiber neuropathy [14]. Kass-
Iliyya et al. recently showed that corneal confocal microscopy could be used as an 
alternative method to demonstrate non-invasively small nerve fiber damage in PD 
[15]. In this study it was shown that patients with PD have an increased corneal 
nerve fiber length and corneal nerve branching density, as well as a decreased 
corneal nerve fiber density. However, these results were exactly opposite to the 
ones reported in a study conducted by Podgorny et al. who showed that patients 
with early PD (drug naïve or recently started on treatment) had significantly reduced 
corneal nerve fiber densities and lengths compared to controls [16]. Although both 
studies included small number of patients, and therefore might be underpowered, 
the contradictory results could also possibly be explained by the fact that the study 
by Podgorny et al. mainly involved drug-naïve or early treated patients [16]. 
 
SFN in PD has been reported since 2008 when Novak et al. demonstrated reduced 
small fiber density in skin biopsies from patients with PD [17]. Nolano et al. 
performed quantitative sensory testing and skin biopsies in patients with PD and 
found a significant increase in tactile and thermal thresholds, a significant reduction 
in mechanical pain perception and a significant loss of epidermal nerve fibers (ENFs) 
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and Meissner corpuscles (MCs) in patients with PD compared to controls [18, 19]. 
Reported prevalence of SFN, as this was determined by the intra-epidermal nerve 
fiber density, ranges from 37% [20] to 91% [21]. The pooled estimate of the 
prevalence of small fiber neuropathy based on the skin biopsy as this has been 
reported in 3 studies of a total of 72 patients with PD is 56.9% [20 – 22]. Given the 
small number of participants in each study this figure should be interpreted with 
caution. 
 
Neurophysiological types of chronic neuropathy in PD 
 
Large fiber neuropathies can be broadly classified as axonal, where axons are 
affected most commonly in proportion to their length (length-dependent 
polyneuropathy) or demyelinating, affecting the myelin sheath around axons and 
impairing the ability of the axons to speedily conduct electrical impulses resulting in 
slow conduction or conduction block [1]. 
 
Neuropathy in PD is in the majority of cases distal, symmetrical, axonal and 
predominantly sensory. There are, however, few reports of chronic inflammatory 
demyelinating polyneuropathy (CIDP). In their study, Toth et al. reported that out of 
49 patients with PD and PN, 94% had sensorimotor axonal neuropathy and 6% had 
CIDP [23]. In a case series reported by Gondim Fde et al., 1 out of 10 patients 
reported had CIDP [24]. A case of distal acquired demyelinating symmetric (DADS) 
neuropathy – which is considered a subtype of CIDP – has been recently reported by 
McGinty et al. [25] and has been linked with the anti-TNF-α therapy that the patient 
was receiving for his rheumatoid arthritis.  Such reports of patients with PD with co-
incident autoimmune diseases [26] suggest a possible role of the immune system in 
the pathogenesis of at least some cases of neuropathy in PD 
 
Acute polyneuropathies  
 
Isolated cases of patients with PD who developed acute polyneuropathies have been 
reported. The first such report was by Rajabally et al. [27] who described a patient 
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who developed acute motor axonal neuropathy (AMAN) following Campylobacter 
jejuni infection. Acute inflammatory demyelinating polyneuropathy (classical 
Guillain-Barre syndrome) with positive anti-ganglioside antibodies has been reported 
by Galazky et al. during intrajejunal levodopa infusion therapy [28].  
 
Pathological findings - nerve biopsies 
 
Sural nerve biopsies have been reported in 2 patients with PD who had developed 
sub-acute axonal neuropathy associated with cobalamin and vitamin B6 deficiency 
during intestinal levodopa therapy. The biopsies showed reduction in myelinated 
nerve fiber density and endoneurial oedema. Myelin debris was found in several 
endoneurial macrophages, indicating recent nerve fiber breakdown. Inflammatory 
infiltrates of CD8-immunoreactive T-cells were absent [29]. Evidence of 
inflammatory changes (perivascular lymphocytic cuffing) had been found in sural 
nerve biopsies in one of 3 patients reported by Kimber et al. [30] when mild 
inflammatory infiltration lymphocytes in one out of 2 patients repored by Cáceres-
Redondo et al. [31] 
 
Vital et al. conducted a pathological study of peripheral nerves from patients with 
PN and demonstrated intra-axonal ubiquitin aggregates were more numerous in the 
patients with PN and PD compared to patients without PD [32]. It is possible that the 
prevalence of ubiquitin aggregates in patients with PD is the consequence of the 
underlying neurodegenerative process [32]. 
 
Pathological findings – skin biopsies 
 
Small fiber density is reduced in PD compared with healthy controls [15, 18 - 21] and 
patients with parkinsonism [17, 21] suggesting than skin biopsy may be also 
contribute to the differential diagnosis of IPD and parkinsonism [21]. 
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Wang et al. studied the α-synuclein deposition in cutaneous sensory nerves and 
showed that is increased in cutaneous sympathetic adrenergic and sympathetic 
cholinergic fibers but not sensory fibers of patients with PD compared to controls 
[21]. Donadio et al. showed that neuritic α-synuclein inclusions are correlated with a 
small-fiber neuropathy suggesting a possible direct role of phosphorylated α-
synuclein in peripheral nerve fiber damage [33].  
 
Risk factors and role of levodopa 
 
The term idiopathic neuropathy refers to those neuropathies where no aetiology can 
be identified despite extensive and appropriate investigations  [1]. The reported 
prevalence of idiopathic neuropathies among patients with PD varies widely, and 
investigations about possible causes of polyneuropathy may have been incomplete 
in some reports [1]. Some studies included in this review have not stated whether 
extensive thorough investigations were done to identify potential risk factors [34, 
35] or, in other studies, the authors have only checked for very common risk factors 
such as alcohol exposure, diabetes and hypovitaminosis [10, 32, 36, 37]. 
 
Toth et al. reported the largest case series of patients with PD and PN [23]. Out of 49 
patients with PD and PN, 8 patients were found to have diabetes or impaired glucose 
tolerance, 4 patients monoclonal gammopathy of uncertain significance and 3 
patients had CIDP. Idiopathic PN was identified in 34 patients with PD. However, 32 
of these (94%) had abnormalities in vitamin B12, fasting methylmalonic acid (MMA) 
or fasting homocysteine concentrations (Hcy), leaving only 2 patients (4.1% of the 
case series) with truly idiopathic neuropathy. In this study, it was suggested that 
cumulative lifetime levodopa dosage and fasting MMA levels were associated with 
PN severity and concluded that PN in PD may either be associated with iatrogenic 
cobalamin metabolic abnormalities or be a peripheral nervous system manifestation 
of PD [23]. Increased Hcy and low B12 levels have been reported in smaller case 
series of patients with PD and PN [29 -31, 38 – 43].  
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Ceravolo et al. reported that the risk of neuropathy in PD is independently 
associated only to age and duration of exposure to levodopa and is not influenced by 
disease duration, disease severity, serum vitamin B12 or serum Hcy level [8].  
 
Data on levodopa-naïve patients show that there is no difference between the 
epidermal nerve fiber density in treated and untreated patients, suggesting that 
epidermal nerve fiber density is unrelated to drug treatment [19]. In a study 
conducted by Shahrizaila et al. the electrodiagnostic criteria for distal symmetric 
polyneuropathy were fulfilled in 24% of treated patients and in 23% of untreated 
patients, demonstrating no difference in the prevalence of PN in patients with PD 
taking chronic levodopa therapy versus levodopa-naïve patients [10]. Rajabally et al. 
found that the prevalence of PN in levodopa-naïve patients with PD was significantly 
lower compared to levodopa treated (12.1% versus 36.1%) after a regression 
analysis they concluded that neuropathy was only independently associated with 
age and serum folate concentration [42]. 
 
Protective role of COMT 
 
In a recent study Cossu et al compared 144 patients with PD who have been on 
levodopa for more than three years not receiving entacapone with 53 patients who 
have also been on levodopa for more than three years, but were also receiving 
entacapone [44]. The prevalence of neuropathy in the latter group (prevalence 5.7%) 
was significantly lower than the patients not receiving entacapone (prevalence 
19.4%).  This finding, suggests that the use of catechol-O-methyltransferase-
inhibitors could have a protective effect on the development of PN.  
 
 
Intestinal levodopa infusion studies 
 
The first reports of PN during continuous intestinal infusion of levodopa suggested 
that patients might develop subacute PN secondary to hypovitaminosis, mainly B12 
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deficiency [29, 38, 39, 45], although isolated case reports described patients with 
subacute PN without cobalamin deficiency [46]. 
 
In a small case controlled study of intestinal levodopa infusion versus oral drugs, 
Jugel et al. reported that neurophysiological abnormalities were more severe in the 
group who had intestinal levodopa infusion [35]. Contrary to this finding, Mancini et 
al. in a large case controlled study compared the prevalence of PN in patients on 
intestinal levodopa infusion with patients on oral levodopa and with patients on 
other dopaminergic treatment, and found a higher prevalence of PN in patients 
treated with intestinal levodopa (28%) and oral levodopa treated patients (20%) 
compared to patients on other dopaminergic treatments (6%). No difference 
between the intestinal and oral levodopa groups was observed [37]. 
 
In a prospective study of assessment of PN during intestinal levodopa infusion, 
Merola et al. reported that intestinal levodopa infusion may worsen the 
neurophysiological and clinical features of pre-existing polyneuropathy, but these 
alterations are similar to those described during oral levodopa treatment [41]. The 
same group recently published their experience on 33 consecutive patients treated 
with intestinal levodopa infusion [47]. Of these, 10 patients (30.3%) had clinical or 
electrophysiological evidence of PN before the treatment with the intestinal 
levodopa infusion. Of the remaining 23 patients, almost half (47.8%) developed 
neuropathy during the intestinal levodopa infusion treatment; 2 developed subacute 
PN and 9 developed chronic PN (2 with clinical signs and 7 only with 
electrophysiological evidence). 
 
Chang et al. suggested that clinicians should monitor for PN and for hypovitaminoses 
during intestinal levodopa infusion, as vitamin supplementation can reverse PN [40]. 
In a pilot prospective study assessing small nerve fiber impairment following 
intestinal levodopa infusion in 5 patients, Devigili et al showed that intestinal 
levodopa infusion could cause severe skin denervation and increased thermal 
thresholds [48]. Epidermal denervation occured soon after starting treatment; 
axonal swellings and intraepidermal nerve fiber density reduction were detected 
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after 3 months, while almost complete denervation of the epidermis and dermal 
bundles appeared at 6 months [48]. 
 
 
Conclusion 
 
The pooled estimate of the prevalence of large fiber neuropathy in idiopathic PD is 
estimated to be 16.3%. This is significantly higher compared to the prevalence of PN 
in the general population. However, this figure should be interpreted with caution, 
given the heterogeneity of the study populations and the fact that in some studies 
patients with risk factors such as diabetes and excessive alcohol consumption were 
excluded. Therefore, the prevalence of PN in PD might be even greater. In addition, 
the extent of investigations looking at other causes of PN in these patients was 
variable and often limited. 
 
The role of levodopa on the development of PN is unclear. One study, showed that 
levodopa is independently associated to PN [42], however the number of patients in 
that study was too small securely to conclude that levodopa directly is responsible 
for the development of PN in PD. Available data on levodopa-naïve patients – which 
are especially important when describing populations of patients with PD [49 – 51] – 
have not shown difference in the prevalence of PN compared to levodopa treated 
patients. On the other hand the majority of studies showed that in most PD cases PN 
is associated with abnormalities in vitamin B12, MMA or and Hcy levels . Such 
abnormalities can occur as a result of malabsorption and it has been hypothetised 
that levodopa treatment might affect the vitamin absorption [52]. 
 
Although the number of studies of PN in PD is increasing, the number of patients 
with PD and PN reported in each is small. The largest study to date has included 49 
patients with the combination of PD and PN [23]. Large-scale prospective studies 
with long-term follow-up with detailed baseline assessments are needed in order to 
understand the natural history of PN in PD, both on clinical and neurophysiological 
parameters. 
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Diagnosing PN based on symptom prevalence assessed by checklists and 
questionnaire has a risk of overestimating the prevalence of PN. This is exaggerated 
by the fact that patients with PD may experience sensory symptoms, i.e. neuropathic 
pain of central origin [53] rather than symptoms secondary to PN. PN can only be 
confirmed by neurophysiological assessment. In most studies included in this review 
nerve conduction studies (NCS) have been performed and data have been provided, 
however the NCS included only a limited number of nerves, mainly in the lower 
limbs. The differences in the techniques, the incomplete NCS and the lack of 
normative age-corrected data may influence the apparent prevalence of PN in PD. 
Although many centers have different ways to determine neurophysiologically the 
presence of neuropathy, sensory conduction studies of sural and radial nerves are 
recommended for the diagnosis of a mild axonal predominantly sensory neuropathy 
[54]. This should be complemented with at least one motor study, commonly of the 
tibial nerve [55], to confirm motor involvement. Early SFN assessment, involving 
quantitative sensory testing and corneal confocal microscopy may be a useful 
approach to the diagnosis of PN as it is known that at least some patients evolve 
from a strict SFN to large fiber PN [56, 57]. 
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Table 1. Characteristics of papers included in the review. Full details for each 
study are available as an online Supplement 
 
Types of publications 
Case Reports 
Case Series / Open label studies 
Case – controlled studies 
 
4 
18 
16 
Number of all PD patients studied 
Total number of PD patients  
Range 
Mean number of patients per study (SD) 
Median 
 
1,651 
1 – 500 
43.4 (94.5) 
20 
Demographics of all PD patients studied* 
Male : Female 
Mean age 
Mean disease duration 
 
3:2 
66.1 years 
7.9 years 
Number of all PD patients with PN studied** 
Total number of PD patients  
Range 
Mean number of patients per study (SD) 
Median 
 
258 
1 – 49 
7.6 (11.8) 
3 
Demographics of all PD patients with PN 
studied* 
Male : Female 
Mean age 
Mean disease duration 
 
3:2 
69.4 years 
8.6 years 
Year of publication 
Range 
 
1991 to 2016 
Number of publications per decade 
Until 2000 
2000 - 2009 
2011 – now 
 
1 
6 
31 
*where data were provided 
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**large fiber PN confirmed electrophysiologically 
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Highlights 
 The prevalence of large fiber neuropathy in idiopathic PD is estimated to be 
16% 
 The role of levodopa on the development of PN is still unclear 
 Large studies with neurophysiologically confirmed neuropathy in PD are 
needed 
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